Inventor
RAJKUMAR GANESAN
Inventor
US
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
C07KPeptides29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C12NMicroorganisms or enzymes10%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
PatentTitleYear
12,528,879Multi-specific binding proteins for cancer treatment202612,522,658Anti-CD79 chimeric antigen receptors, CAR-T cells, and uses thereof202612,492,256Methods and compositions for modulating beta chain mediated immunity202512,492,226Materials and methods for producing bioengineered virus specific lymphocytes202512,460,001Proteins comprising CD3 antigen binding domains and uses thereof202512,448,449Immune targeting molecules and uses thereof202512,264,197Anti-Vb17/anti-CD123 bispecific antibodies202512,180,278Antibody targeting CD22 and CD79B202412,173,083Multi-specific binding proteins for cancer treatment202412,134,658Materials and methods for multidirectional biotransportation in virotherapeutics202412,129,310Materials and methods for enhanced linker targeting202412,103,977Trispecific antibody targeting CD79b, CD20, and CD3202412,084,501Proteins comprising CD3 antigen binding domains and uses thereof202412,077,585Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses202412,076,413Compositions and methods for modulating delta gamma chain mediated immunity202412,077,592GPRC5D chimeric antigen receptors and cells expressing the same202412,071,466Anti-human kallikrein-2 (hK2) chimeric antigen receptor (CAR) and methods of use thereof202411,981,932Materials and methods for the manufacture of pluripotent stem cells202411,965,024Methods and compositions for modulating beta chain mediated immunity202411,952,411Materials and methods of using engineered ligands202411,926,667Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII202411,866,499Monospecific and multispecific anti-TMEFF2 antibodies and their uses202411,827,708Proteins comprising HLA-G antigen binding domains and their uses202311,732,045Multi-specific binding proteins for cancer treatment202311,667,712Materials and methods for modulating t cell mediated immunity202311,639,396Antibody binding to a linker peptide202311,332,541Multi-specific binding proteins for cancer treatment202211,312,785Antagonizing CD73 antibody202211,267,880Anti-Sema3A antibodies and their uses for treating eye or ocular diseases202211,236,155Antibodies to pyroglutamate amyloid-b and uses thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to BOEHRINGER INGELHEIM INT (6)· patent assignee history
2022Patents assigned to JANSSEN PHARMACEUTICA NV (1)· patent assignee history
2022–2026Based in US· patent location history
2023–2026Patents assigned to JANSSEN BIOTECH INC (23)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| JANSSEN BIOTECH INC | 23 | 2023–2026 |
| BOEHRINGER INGELHEIM INT | 6 | 2022–2026 |
| JANSSEN PHARMACEUTICA NV | 1 | 2022 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 30 | 2022–2026 |